Skip to main content

Advertisement

SpringerLink
Log in

Serum concentrations of carboxylated osteocalcin are increased and associated with several components of the polycystic ovarian syndrome

  • Original Article
  • Published:
Journal of Bone and Mineral Metabolism Aims and scope Submit manuscript

An Erratum to this article was published on 06 November 2010

Abstract

Intriguing studies suggest that osteocalcin (OC) and its carboxylated (Gla)/uncarboxylated form are involved in the regulation of insulin secretion and action. Additionally, advanced glycated end products (AGEs) directly regulate the secretion of these osteoblast-derived molecules. In polycystic ovarian syndrome (PCOS), among the pathophysiological aberrations, deregulation of insulin secretion and action as well as elevated AGEs levels have been demonstrated. In this study, we evaluated the serum levels of osteocalcin and Gla osteocalcin and their possible associations with metabolic, hormonal, and ultrasonographic components of PSOS: 97 women were studied, 50 PCOS patients and 47 controls, matched for age and body mass index (BMI). In each subject, the levels of bone metabolism markers have been evaluated, and metabolic and hormonal profiles as well as ovarian ultrasound were carried out. Osteocalcin (4.30 ± 1.74 vs. 6.20 ± 1.78 ng/ml, P < 0.0005) values were significantly lower, whereas Gla osteocalcin (37.93 ± 6.87 vs. 9.64 ± 8.21 ng/ml, P < 0.0005) and receptor activator for nuclear factor-κB ligand (0.54 ± 0.26 vs. 0.16 ± 0.15 pmol/l, P < 0.0005) values were significantly higher in PCOS subjects compared to the control group, independently of obesity. A significant association was disclosed between osteocalcin and Gla osteocalcin with androgens, insulin resistance, AGEs, and ovarian morphology. Receiver operating curve analysis revealed that Gla osteocalcin [AUC, 0.975 (95% CI, 0.93–1.00)] as well as AGEs are significant prognostic factors of PCOS [AUC, 0.986 (95% CI, 0.97–1.00)]. Lower osteocalcin and elevated serum levels of its carboxylated form are displayed in PCOS subjects and are associated with several PCOS components. These findings suggest a potential interaction between bone-derived markers and the metabolic/hormonal abnormalities observed in PCOS. However, the pathophysiological mechanisms and moreover the possible clinical implications require further investigation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, Zapanti ED, Bartzis MI (1999) A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocr Metab 84:4006–4011

    Article  PubMed  CAS  Google Scholar 

  2. Goodarzi MO, Erickson S, Port SC, Jennrich RI, Korenman SG (2005) Beta-cell function: a key pathological determinant in polycystic ovary syndrome. J Clin Endocrinol Metab 90:310–315

    Article  PubMed  CAS  Google Scholar 

  3. Lee NK, Karsenty G (2008) Reciprocal regulation of bone and energy metabolism. Trends Endocr Metab 19:161–166

    Article  CAS  Google Scholar 

  4. Ferron M, Hinoi E, Karsenty G, Ducy P (2008) Osteocalcin differentially regulates beta-cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci USA 105:5266–5270

    Article  PubMed  CAS  Google Scholar 

  5. Cassese A, Esposito I, Fiory F, Barbagallo AP, Paturzo F, Mirra P, Ulianich L, Giacco F, Iadicicco C, Lombardi A, Oriente F, Van Obberghen E, Beguinot F, Formisano P, Miele C (2008) In skeletal muscle advanced glycation end products (AGEs) inhibit insulin action and induce the formation of multimolecular complexes including the receptor for AGEs. J Biol Chem 283:36088–36099

    Article  PubMed  CAS  Google Scholar 

  6. Franke S, Siggelkow H, Wolf G, Hein G (2007) Advanced glycation end products influence the mRNA expression of RAGE, RANKL and various osteoblastic genes in human osteoblasts. Arch Phys Biochem 113:154–161

    Article  CAS  Google Scholar 

  7. Diamanti-Kandarakis E, Livadas S, Kandarakis SA, Margeli A, Papasotiriou I (2008) Low free plasma levels of retinol-binding protein 4 in insulin-resistant subjects with polycystic ovary syndrome. J Endocrinol Invest 31:950–954

    PubMed  CAS  Google Scholar 

  8. Panidis D, Balaris C, Farmakiotis D, Rousso D, Kourtis A, Balaris V, Katsikis I, Zournatzi V, Diamanti-Kandarakis E (2005) Serum parathyroid hormone concentrations are increased in women with polycystic ovary syndrome. Clin Chem 51:1691–1697

    Article  PubMed  CAS  Google Scholar 

  9. Diamanti-Kandarakis E, Piouka A, Livadas S, Piperi C, Katsikis I, Papavassiliou AG, Panidis D (2008) Antimullerian hormone is associated with advanced glycosylated end products in women with polycystic ovary syndrome. Eur J Endocr 158:525–531

    Article  CAS  Google Scholar 

  10. Young MF (2003) Bone matrix proteins: their function, regulation, and relationship to osteoporosis. Osteoporos Int 14:S35–S42

    PubMed  CAS  Google Scholar 

  11. Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, Dacquin R, Mee PJ, McKee MD, Jung DY, Zhang Z, Kim JK, Mauvais-Jarvis F, Ducy P, Karsenty G (2007) Endocrine regulation of energy metabolism by the skeleton. Cell 130:456–469

    Article  PubMed  CAS  Google Scholar 

  12. Horiuchi T, Kazama H, Araki A, Inoue J, Hosoi T, Onouchi T, Mizuno S, Ito H, Orimo H (2004) Impaired gamma carboxylation of osteocalcin in elderly women with type II diabetes mellitus: relationship between increase in undercarboxylated osteocalcin levels and low bone mineral density. J Bone Miner Metab 22:236–240

    Article  PubMed  CAS  Google Scholar 

  13. Kindblom JM, Ohlsson C, Ljunggren O, Karlsson MK, Tivesten A, Smith U, Mellström D (2009) Plasma osteocalcin is inversely related to fat mass and glucose in elderly Swedish men. J Bone Miner Res 24:785–791

    Article  PubMed  CAS  Google Scholar 

  14. Im JA, Yu BP, Jeon JY, Kim SH (2008) Relationship between osteocalcin and glucose metabolism in postmenopausal women. Clin Chim Acta 396:66–69

    Article  PubMed  CAS  Google Scholar 

  15. Hwang YC, Jeong IK, Kyu JA, Chung HO (2009) The uncarboxylated form of osteocalcin is associated with improved glucose tolerance and enhanced β-cell function in middle-aged male subjects. Diabetes Metab Res Rev 25:768–772

    Article  PubMed  CAS  Google Scholar 

  16. Shea MK, Gundberg CM, Meigs JB, Dallal GE, Saltzman E, Yoshida M, Jacques PF, Booth SL (2009) γ-Carboxylation of osteocalcin and insulin resistance in older men and women. Am J Clin Nutr 90:1230–1235

    Article  PubMed  CAS  Google Scholar 

  17. Kanazawa I, Yamaguchi T, Yamamoto M, Kurioka S, Yano S, Sugimoto T (2009) Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus. J Clin Endocr Metab 94:45–49

    Article  PubMed  CAS  Google Scholar 

  18. Schurman L, McCarthy AD, Sedlinsky C, Gangoiti MV, Arnol V, Bruzzone L, Cortizo AM (2008) Metformin reverts deleterious effects of advanced glycation end-products (AGEs) on osteoblastic cells. Exp Clin Endocr Diabetes 116:333–340

    Article  CAS  Google Scholar 

  19. Escobar-Morreale HF, Botella-Carretero JI, Martinez-Garcia MA, Luque-Ramírez M, Alvarez-Blasco F, San Millán JL (2008) Serum osteoprotegerin concentrations are decreased in women with the polycystic ovary syndrome. Eur J Endocrinol 159:225–232

    Article  PubMed  CAS  Google Scholar 

  20. Adami S, Zamberlan N, Castello R, Tosi F, Gatti D, Moghetti P (1998) Effect of hyperandrogenism and menstrual cycle abnormalities on bone mass and bone turnover in young women. Clin Endocr (Oxf) 48:169–173

    Article  CAS  Google Scholar 

  21. Glintborg D, Andersen M, Hagen C, Heickendorff L, Hermann AP (2008) Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial. J Clin Endocr Metab 93:1696–1701

    Article  PubMed  CAS  Google Scholar 

  22. Vega D, Maalouf NM, Sakhaee K (2007) Clinical review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications. J Clin Endocr Metab 92:4514–4521

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

All authors have nothing to disclose.

Author information

Authors and Affiliations

  1. Endocrine Section, First Department of Medicine, University of Athens Medical School, Mikras Asias 75, Goudi, 115-27, Athens, Greece

    Evanthia Diamanti-Kandarakis, Sarantis Livadas & Mantziou Aimilia

  2. Division of Endocrinology and Human Reproduction, Second Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, 119, Mitropoleos Str., 54622, Thessaloniki, Greece

    Ilias Katsikis & Dimitrios Panidis

  3. Laboratory of Biological Chemistry, University of Athens Medical School, Mikras Asias 75, Goudi, 115-27, Athens, Greece

    Christine Piperi & Athanasios G. Papavassiliou

Authors
  1. Evanthia Diamanti-Kandarakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sarantis Livadas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ilias Katsikis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Christine Piperi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mantziou Aimilia
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Athanasios G. Papavassiliou
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Dimitrios Panidis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Evanthia Diamanti-Kandarakis.

Additional information

An erratum to this article can be found at http://dx.doi.org/10.1007/s00774-010-0238-4

About this article

Cite this article

Diamanti-Kandarakis, E., Livadas, S., Katsikis, I. et al. Serum concentrations of carboxylated osteocalcin are increased and associated with several components of the polycystic ovarian syndrome. J Bone Miner Metab 29, 201–206 (2011). https://doi.org/10.1007/s00774-010-0211-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00774-010-0211-2

Keywords

Search

Navigation